Proceedings of the National Academy of Sciences · 2016 · 143 citations · 36 references
Life SciencesMolecular BiologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseBrain Energy MetabolismNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease Gene TherapyAlzheimer Disease NeuroprotectionAlzheimer's Disease ModelsAmyloid Beta PlaquesEnergy Metabolism In NeurodegenerationNeuronal DysfunctionViral Expression VectorsViral Vectors
Current therapies for Alzheimer's disease (AD) are symptomatic and do not target the underlying Aβ pathology and other important hallmarks including neuronal loss. PPARγ-coactivator-1α (PGC-1α) is a cofactor for transcription factors including the peroxisome proliferator-activated receptor-γ (PPARγ), and it is involved in the regulation of metabolic genes, oxidative phosphorylation, and mitochondrial biogenesis. We previously reported that PGC-1α also regulates the transcription of β-APP cleaving enzyme (BACE1), the main enzyme involved in Aβ generation, and its expression is decreased in AD patients. We aimed to explore the potential therapeutic effect of PGC-1α by generating a lentiviral vector to express human PGC-1α and target it by stereotaxic delivery to hippocampus and cortex of APP23 transgenic mice at the preclinical stage of the disease. Four months after injection, APP23 mice treated with hPGC-1α showed improved spatial and recognition memory concomitant with a significant reduction in Aβ deposition, associated with a decrease in BACE1 expression. hPGC-1α overexpression attenuated the levels of proinflammatory cytokines and microglial activation. This effect was accompanied by a marked preservation of pyramidal neurons in the CA3 area and increased expression of neurotrophic factors. The neuroprotective effects were secondary to a reduction in Aβ pathology and neuroinflammation, because wild-type mice receiving the same treatment were unaffected. These results suggest that the selective induction of PGC-1α gene in specific areas of the brain is effective in targeting AD-related neurodegeneration and holds potential as therapeutic intervention for this disease.
36
Martin Prince, Anders Wimo, Maëlenn Guerchet et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 2015 · 2.3K citations · Full text
Julie St‐Pierre, Stavit Drori, Marc Uldry et al. · Cell · 2006 · 2.2K citations · Full text
Exercise Induces Hippocampal BDNF through a PGC-1α/FNDC5 Pathway
Christiane D. Wrann, James P. White, John Salogiannnis et al. · Cell Metabolism · 2013 · 1.4K citations · Full text
Medicine, Neurobiology, Neuroscience +11
Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice
Jiandie D. Lin, Pei-Hsuan Wu, Paul T. Tarr et al. · Cell · 2004 · 1.2K citations · Full text